1. Variable temperature-nuclear magnetic resonance experiment and high-resolution MS/MS n measurement of hydroxycarbodenafil, and its PDE5 inhibitory activity.
- Author
-
Tachikawa H, Nishiyama R, Kosugi Y, Ichikawa-Kaji Y, Uemura N, Moriuchi Y, Moriyasu T, Suzuki T, and Inomata A
- Subjects
- Crystallography, X-Ray methods, Tandem Mass Spectrometry methods, Cyclic Nucleotide Phosphodiesterases, Type 5 metabolism, Cyclic Nucleotide Phosphodiesterases, Type 5 chemistry, Piperazines chemistry, Piperazines pharmacology, Piperazines analysis, Phosphodiesterase 5 Inhibitors chemistry, Phosphodiesterase 5 Inhibitors analysis, Phosphodiesterase 5 Inhibitors pharmacology, Magnetic Resonance Spectroscopy methods, Temperature
- Abstract
Hydroxycarbodenafil, an analogue of carbodenafil, was detected in a dietary supplement in China in 2020. However, previous reports have not identified some carbon signals from the piperazine ring in nuclear magnetic resonance (NMR) experiments. Because the compound contains an amide bond, the reaction was suggested to be characteristic of compounds with rotational isomers. Variable-temperature NMR is used to determine the rotational barrier between different conformations by changing the measurement temperature. Using this technique, we succeeded in obtaining the first distinct data, including the carbon signals of the piperazine ring in the NMR spectrum of hydroxycarbodenafil. We also confirmed that this technique could be applied to other carbodenafil analogues. Multi-stage mass spectrometry (MS
n ) measurements with a high-resolution mass spectrometer specific to the substructures were performed to develop a protocol for the structural determination of the carbodenafil analogues. In addition, hydroxycarbodenafil was analysed using X-ray crystallography, and its inhibitory activity against phosphodiesterase type 5 (PDE5) was measured. The IC50 value of the inhibitory activity of hydroxycarbodenafil for PDE5A1, a PDE5 isoform, of 2.9 nM was lower than the 4.5 nM for sildenafil, a positive control., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF